IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

NCT04298879 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-hodgkin Lymphoma

Interventions

DRUG: IBI376

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.